Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety endpoints compared to IV KEYTRUDA in combination with chemotherapy
Positions Curium as leading manufacturer of Lu-177 isotope
The first-of-its-kind study will evaluate potential association between GSK’s shingles vaccine and reduced dementia risk, building on growing body of evidence from observational and retrospective studies
Collaboration combines data, identity capture and Web 3.0 crypto technologies to enhance product safety, traceability, and data integrity for AI systems
Abbott's investigational Coronary Intravascular Lithotripsy (IVL) System offers a new potential treatment by using sound pressure waves to treat arterial calcium blockages
Alembic Pharmaceuticals Ltd. and Amlan International sign exclusive strategic commercial agreement to make poultry health innovations accessible to Indian farmers and integrators
Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region
Nadda noted that TB treatment coverage in India has increased from 59% to 85%
Adults taking Mounjaro with diet and exercise in a controlled clinical trial lost on average 21.8 kg at the highest dose (15mg) and 15.4 kg at the lowest dose (5mg)
Alembic Pharmaceuticals successfully completes USFDA inspection for API-III facility
Subscribe To Our Newsletter & Stay Updated
